Integrity Cases: Gene Doping, Racing’s Most Sophisticated Emerging Threat
|
When the BHA’s Equine Anti-Doping Programme was expanded in March 2025 to include testing for gene doping, it marked a significant shift in the sport’s integrity framework, from responding to known threats to anticipating ones that have not yet materialised in British racing. The distinction matters, because gene doping is not a theoretical concern invented by regulators: its use in equestrian sport outside racing has been documented, and the technological barriers to its application in racing are falling.
What Makes Gene Doping Different
Conventional doping, administering prohibited substances, leaves chemical traces in blood, urine or hair samples that analytical laboratories are equipped to find. The entire architecture of equine anti-doping, from detection time guidance to laboratory accreditation, is built around identifying these chemical signatures.
Gene doping operates differently. Instead of introducing a foreign substance that must be metabolised and excreted, gene doping alters the horse’s own cellular machinery, potentially changing how much of a naturally occurring substance (muscle-building protein, oxygen-carrying haemoglobin, recovery hormone) is produced. The edited horse may produce more of a natural substance without receiving anything from outside its own body. Detecting this requires identifying the modification in the horse’s DNA or identifying the delivery vector (the virus or cellular mechanism used to introduce the gene edit), an entirely different analytical challenge from detecting pharmaceutical substances.
The Documented Precedent
The IFHA’s Gene Doping Control Subcommittee, established in 2016 after the threat was first formally identified at international level, has documented examples of genetic manipulation in polo ponies in Argentina. While horse racing has no confirmed cases in any jurisdiction, polo, a sport that places considerable commercial value on equine performance and has somewhat less stringent regulatory oversight than thoroughbred racing, has provided proof of concept that gene editing of sport horses for performance purposes is technically feasible and has been attempted.
The Horse & Hound’s reporting noted that “there are examples of gene editing for performance purposes in ponies bred for polo in Argentina”, the clearest documented case of equine genetic manipulation in competitive sport. FEI Senior Veterinary Adviser Caterina Termine noted at the 2024 FEI Sports Forum that genetic manipulation could be applied to embryos, youngstock and adult horses, meaning the window of vulnerability is not confined to adult athletes in active competition.
The Detection Challenge at LGC
The BHA’s seven-figure investment was directed at LGC’s laboratory in Cambridgeshire, where Dr Edward Ryder, an IFHA subcommittee member, led the development of novel detection methods. Two technical challenges were addressed:
Transgene detection: Identifying whether a horse’s genome contains DNA sequences that are not natural to its species or breed, i.e., sequences introduced through gene transfer from another organism or artificially constructed.
Delivery vector detection: Identifying the viral vectors (typically modified adeno-associated viruses) used to introduce gene edits. These vectors may be detectable in samples even when the gene edit itself is difficult to identify.
Dr James Scarth of LGC described the resulting methodology as deliberately flexible: the tests can be updated to detect new transgenes or delivery vectors as the science of gene editing evolves. This future-proofing is essential in a field where techniques are advancing rapidly, CRISPR-Cas9 and its derivatives, base editing, prime editing and other approaches are progressively making gene editing cheaper, more accessible and more precise.
Regulatory Framework
Gene doping is prohibited under the BHA’s Rules of Racing, as it is in all major racing jurisdictions worldwide, and has been since the regulatory framework was established around it. The prohibition precedes the detection capability: the BHA could not detect gene doping in samples before March 2025, even though the practice was already banned.
The gap between prohibition and detection is a critical vulnerability in any anti-doping system. Athletes or trainers who dope with a substance or technique that cannot be detected face no practical enforcement risk even if they are technically in breach of rules. The BHA’s investment in gene doping detection is therefore as much about closing an enforcement gap as it is about introducing a new prohibition.
The FEI’s parallel action, updating its Equine Prohibited Substances List from 1 April 2025 to explicitly define and prohibit genetic therapy, gene editing and genome editing, coordinated the international regulatory response and ensured that FEI-accredited laboratories had the capacity to test for gene doping in their jurisdictions.
The Breed Protection Dimension
Beyond competitive fairness, gene doping poses a specific threat to the thoroughbred breed. Thoroughbreds are defined by a recorded genetic heritage that extends back to the seventeenth century. Any heritable genetic modification, one that could be passed to offspring, would alter that heritage in ways that cannot be undone, potentially affecting the genetic integrity of the breed for generations.
The BHA and its acting CEO Brant Dunshea were explicit about this dimension: “protecting the thoroughbred breed” was named alongside competitive integrity and horse welfare as a core reason for the testing programme. The Weatherbys studbook, the official register of thoroughbred breeding in Britain, is ultimately a genetic document. An undetected gene-edited horse whose offspring entered the studbook would contaminate that record in ways that conventional medication testing has never threatened.
